ImmunoForge Pursues Global Partnerships at Healthcare Conference
ImmunoForge Co., Ltd., a clinical-stage biopharmaceutical company focusing on rare diseases, is set to engage in strategic partner meetings during a prominent healthcare conference. The leadership team, including Co-CEOs Sung-Min Ahn and Kiho Chang, aims to collaborate with global pharmaceutical companies and investors to enhance their clinical assets.
Focus on Licensing of Key Assets
During the conference, ImmunoForge will prioritize the out-licensing of its significant Phase 2 assets, PF1801 and PF1804. These strategic sessions aim to secure partnerships that facilitate U.S. clinical entry for these promising therapies. The company has opted for high-level private meetings rather than formal presentations, aiming for deeper discussions on the clinical progression and potential licensing agreements.
Notable Clinical Assets for Discussion
ImmunoForge has impressive assets under development, including:
- PF1801 (Polymyositis/Dermatomyositis, DMD & Sarcopenia): Undergoing a Phase 2 trial in South Korea and has received U.S. FDA Phase 2 IND clearance, making it an attractive candidate for immediate U.S. clinical launch via a global partner.
- PF1804 (DMD Cardiomyopathy): Also FDA cleared for Phase 2, ready for clinical initiation.
- PF1807 (Sarcopenia): A monthly therapy focusing on myositis and sarcopenia treatment.
- KF1601 (CML): Licensing discussions are open for international partners following domestic rights agreement prior to Phase 1.
Collaborative Opportunities with Global Pharma
The company actively seeks partners capable of advancing these assets through to clinical phases and into the market. A representative from ImmunoForge stated their goal for the conference week is to engage with potential collaborators who can leverage their cleared INDs for rapid market entry. The company is focused on minimizing risk through regulatory clearances and looking for global collaborators who can lead the next phase of clinical development.
Expanding Development Capabilities
ImmunoForge also emphasizes the importance of expanding their development capabilities. The leadership is keen on introducing their diverse pipeline to global companies, including their proprietary long-acting ELP (Elastin-Like Polypeptide) platform and a newly developed BBB-penetrating platform, both crucial to their future offerings.
Contact Information for Meeting Requests
As part of their proactive outreach, ImmunoForge encourages interested parties to schedule meetings with their team during the conference. Interested individuals are invited to contact the Business Development Team directly through their website.
About ImmunoForge
ImmunoForge is dedicated to creating innovative therapies for muscular and rare diseases. Their lead candidate, PF1801, is in a Phase 2 trial, further highlighting their robust pipeline, including PF1802 (CNS), PF1803 (Osteoarthritis), and KF1601 (Oncology). They are committed to securing co-development and licensing partnerships to facilitate the global delivery of their transformative therapies.
Frequently Asked Questions
What is ImmunoForge's focus during the conference?
ImmunoForge is concentrating on engaging with global pharmaceutical partners to advance their clinical assets and secure strategic licensing agreements.
Which key assets are ImmunoForge discussing?
They are discussing PF1801, PF1804, PF1807, and KF1601 during the strategic meetings.
Where are the meetings taking place?
The meetings are held in San Francisco during the J.P. Morgan Healthcare Conference.
Is ImmunoForge seeking new partners?
Yes, they are actively looking for global partners to help bring their therapies to market.
What technologies does ImmunoForge utilize?
They are focused on their long-acting ELP platform technology to enhance drug delivery.
